Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma

Published:2011-01-18 Issue:1 Volume:109 Page:63-69
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Garcia Jorge A.,Mekhail Tarek,Elson Paul,Wood Laura,Bukowski Ronald M.,Dreicer Robert,Rini Brian I.

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2010.10011.x/fullpdf

Reference29 articles.

1. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2;Bukowski;Cancer,1997

2. Immunotherapy in renal cell carcinoma;Bukowski;Oncology (Huntingt),1999

3. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma;Bukowski;Semin Oncol,2000

4. Cytokine therapy for metastatic renal cell carcinoma;Bukowski;Semin Urol Oncol,2001

5. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma;Motzer;J Clin Oncol,2000

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;BMC Cancer;2021-07-05

2. Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials;JCO Precision Oncology;2021-06

3. Peniskarzinom;Urologische Tumoren;2018

4. Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma;Oncotarget;2016-03-21

5. A Chemically Defined Trifunctional Antibody–Cytokine–Drug Conjugate with Potent Antitumor Activity;Molecular Cancer Therapeutics;2014-09-09